Torthaí cuardaigh - Pascale Fouqueray

  • 1 - 13 toradh as 13 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial

    Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial de réir Julie Dubourg, Kohjiro Ueki, Jean‐Marie Grouin, Pascale Fouqueray

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes

    Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes de réir Giovanni Pacini, Andrea Mari, Pascale Fouqueray, Sébastien Bolze, Michael Roden

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes

    Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes de réir Pascale Fouqueray, Xavier Leverve, Éric Fontaine, Mathurin Baquié, Claes B. Wollheim

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

    Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Mul... de réir Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean‐Marie Grouin, Kohjiro Ueki

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 2): A 52‐week, open‐label, multicentre phase 3 trial

    Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 2): A 52‐w... de réir Julie Dubourg, Pascale Fouqueray, Damien Quinslot, Jean‐Marie Grouin, Kohei Kaku

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

    Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action de réir Sophie Hallakou‐Bozec, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, David E. Moller

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period

    Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (<scp>TIMES</scp> 3): A randomized, double‐blind, placebo‐controlled phase... de réir Caroline Reilhac, Julie Dubourg, Carole Thang, Jean‐Marie Grouin, Pascale Fouqueray, Hirotaka Watada

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy de réir Pascale Fouqueray, Valdis Pīrāgs, Silvio E. Inzucchi, Clifford J. Bailey, Guntram Schernthaner, Michaëla Diamant, Harold E. Lebovitz

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy

    The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy de réir Pascale Fouqueray, Valdis Pīrāgs, Michaëla Diamant, Guntram Schernthaner, Harold E. Lebovitz, Silvio E. Inzucchi, Clifford J. Bailey

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration

    Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration de réir Dominique Détaille, Guillaume Vial, Anne‐Laure Borel, Cécile Cottet-Rouselle, Sophie Hallakou‐Bozec, Sébastien Bolze, Pascale Fouqueray, Éric Fontaine

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

    Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes de réir Sophie Hallakou‐Bozec, Guillaume Vial, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, Anne‐Laure Borel, Éric Fontaine, David E. Moller

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents

    Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents de réir Rachel J. Perry, Rebecca Cardone, Max C. Petersen, Dongyan Zhang, Pascale Fouqueray, Sophie Hallakou‐Bozec, Sébastien Bolze, Gerald I. Shulman, Kitt Falk Petersen, Richard G. Kibbey

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity

    Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity de réir Vincent Jacques, Sébastien Bolze, Sophie Hallakou‐Bozec, Anthony W. Czarnik, Ajit S. Divakaruni, Pascale Fouqueray, Anne N. Murphy, Lex H.T. Van der Ploeg, Sheila H. DeWitt

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: